Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 6/2011

01-06-2011 | Research Articles

The prognostic value of hTERT expression levels in advanced-stage colorectal cancer patients: a comparison between tissue and serum expression

Authors: María José Safont, Mireia Gil, Rafael Sirera, Eloísa Jantus-Lewintre, Elena Sanmartín, Sandra Gallach, Cristina Caballero, Nieves del Pozo, Eugenio Palomares, Carlos Camps

Published in: Clinical and Translational Oncology | Issue 6/2011

Login to get access
Metadata
Title
The prognostic value of hTERT expression levels in advanced-stage colorectal cancer patients: a comparison between tissue and serum expression
Authors
María José Safont
Mireia Gil
Rafael Sirera
Eloísa Jantus-Lewintre
Elena Sanmartín
Sandra Gallach
Cristina Caballero
Nieves del Pozo
Eugenio Palomares
Carlos Camps
Publication date
01-06-2011
Publisher
Springer Milan
Published in
Clinical and Translational Oncology / Issue 6/2011
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-011-0673-2

Other articles of this Issue 6/2011

Clinical and Translational Oncology 6/2011 Go to the issue

Educational Series

PET-CT in the staging and treatment of non-small-cell lung cancer

Research Articles

The EORTC information questionnaire, EORTC QLQ-INFO25. Validation study for Spanish patients

Research Articles

Limited impact of palliative chemotherapy on survival in advanced solid tumours in patients with poor performance status

Research Articles

Gene expression signature and response to the use of leucovorin, fluorouracil and oxaliplatin in colorectal cancer patients

Research Articles

Phase II clinical trial with gemcitabine and paclitaxel sequential monotherapy as first-line treatment for advanced non-small-cell lung cancer (SLCG 01-04)

Educational Series

microRNAs as novel epigenetic biomarkers for human cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits